News
-
Amneal Pharmaceuticals announced that it has launched a generic over-the-counter naloxone nasal spray for the reversal of opioid overdose after its ANDA for the product was approved by the FDA. Amneal had announced the agency’s… Read more . . .
-
Krystal Biotech has announced the initiation of the KYANITE-1 Phase 1 trial of inhaled KB707 gene therapy in patients with advanced solid lung tumors. Inhaled KB707 received Fast Track designation from the FDA for this… Read more . . .
-
Kindeva Drug Delivery has announced the appointment of Denis Johnson as Chief Operating Officer. Johnson was most recently Head of Global Manufacturing at Biogen and had previously served in executive roles at Catalent Pharma Solutions and Boston… Read more . . .
-
Firebrick Pharma announced that it has launched Nasodine povidone-iodine nasal spray in the US via direct sales through a web site. The company said that it will not make any therapeutic claims so that the… Read more . . .
-
Kimberly Shepard is Director, Respiratory Delivery, at Lonza You presented a workshop at RDD 2023 subtitled, “From small molecules to all molecules” — can all biotherapeutics really be spray dried for inhalation? Besides being a… Read more . . .
-
According to Orexo, the United States Patent and Trademark Office (USPTO) has granted US Patent No. 11,957,647 (“Pharmaceutical composition comprising adrenaline”), which covers Orexo’s OX640 epinephrine nasal powder product. The USPTO previously issued US patent… Read more . . .
-
Inhalation CDMO Vectura has partnered with Mundipharma to reformulate Flutiform fluticasone propionate / formoterol fumarate MDI using a lower global warming potential (LGWP) propellant, the companies announced. According to the announcement, the first step in the reformulation… Read more . . .
-
According to inhaler monitor company Adherium, the FDA has cleared the Hailie Smartinhaler sensor for use with the Airsupra albuterol / budesonide MDI and with the Breztri Aerosphere budesonide / glycopyrronium / formoterol fumarate MDI,… Read more . . .
-
Pulmocide announced that the Phase 2 OPERA-S study of PC945 inhaled opelconazole in lung transplant patients demonstrated that the inhalation suspension was generally safe and well tolerated, with no subjects needing to discontinue or reduce… Read more . . .
-
Silo Pharma announced that it will exercise an option for an exclusive worldwide license to develop SPC-14, an intranasal therapy for the treatment of Alzheimer’s disease, from Columbia University. Silo says that it expects the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK